Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.

Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03237377
Recruitment Status : Recruiting
First Posted : August 2, 2017
Last Update Posted : September 23, 2019
Sponsor:
Collaborator:
AstraZeneca
Information provided by (Responsible Party):
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Brief Summary:
This is a pilot study of neoadjuvant 'immunoradiation' (durvalumab or durvalumab plus tremelimumab) administered every 4 weeks for 2 doses, concurrently with standard thoracic radiation (RT) (45Gy in 25 fractions), with one dose of immunotherapy alone delivered in the pre-surgical window, prior to surgical resection, for patients with stage IIIA NSCLC that is deemed resectable with a lobectomy by a thoracic surgeon. If preliminary safety of the durvalumab/thoracic RT combination is established, a second cohort investigating the combination of durvalumab/tremelimumab/thoracic RT prior to surgical resection will be opened. After surgical resection, patients may receive standard adjuvant chemotherapy, as deemed appropriate by the treating investigator.

Condition or disease Intervention/treatment Phase
Non-Small Cell Lung Cancer Drug: Durvalumab Drug: Tremelimumab Radiation: Thoracic Radiation Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 32 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Neoadjuvant Immunoradiation for Stage III Resectable Non-Small Cell Lung Cancer
Actual Study Start Date : December 12, 2017
Estimated Primary Completion Date : September 2021
Estimated Study Completion Date : September 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer
Drug Information available for: Durvalumab

Arm Intervention/treatment
Experimental: Durvalumab with Radiation Drug: Durvalumab
1500mg via IV infusion every 4 weeks for up to 3 doses/cycles

Radiation: Thoracic Radiation
5 days per week in once daily fractionation, 1.8-2.0 Gy per fraction

Experimental: Durvalumab and Trememlimumab with Radiation Drug: Durvalumab
1500mg via IV infusion every 4 weeks for up to 3 doses/cycles

Drug: Tremelimumab
75mg via IV infusion every 4 weeks

Radiation: Thoracic Radiation
5 days per week in once daily fractionation, 1.8-2.0 Gy per fraction




Primary Outcome Measures :
  1. Toxicities as measured by number of participants experiencing adverse events [ Time Frame: Up to 100 days ]
    Number of participants experiencing adverse events as defined by CTCAE v4.0.

  2. Feasibility of Preoperative Immunoradiation [ Time Frame: Up to 3 years ]
    Number of participants with stage III resectable NSCLC who received durvalumab or durvalumab plus tremelimumab concurrently with thoracic radiation (RT) in the pre-surgical window prior to surgical resection, for whom planned surgical resection was not delayed.


Secondary Outcome Measures :
  1. Surgical Morbidity and Mortality [ Time Frame: Up to 3 years ]
    Number of participants who experience post-operative death. Calculated through log-rank test and Cox proportional hazards (PH) model.

  2. Percentage of Participants with Pathologic Response [ Time Frame: Up to 3 years ]
    Percentage of participants with major pathologic response (MPR), partial response (PR) or no response (NR), where MPR is >90% reduction in tumor cells, PR = 10-90% or NR = 0-10%. The percentage of patients whose tumor samples achieve MPR, PR and NR will be tabulated.

  3. Percentage of Participants with Radiologic Response [ Time Frame: Up to 3 years ]
    Percentage of participants with complete response (CR), partial response (PR), progressive disease (PD), and stable disease (SD) as defined by RECIST 1.1 and immune-related RECIST criteria when treated with preoperative immunoradiation followed by surgery. CR = disappearance of all target lesions, PR is =>30% decrease in sum of diameters of target lesions, PD is >20% increase in sum of diameters of target lesions, SD is <30% decrease or <20% increase in sum of diameters of target lesions.

  4. Duration of Response as measured by recurrence-free survival [ Time Frame: Up to 3 years ]
    Time from first evidence of response until recurrence when treated with preoperative immunoradiation followed by surgery. Calculated through log-rank test and Cox proportional hazards (PH) model.

  5. Overall Survival [ Time Frame: Up to 3 years ]
    Number of months alive after treatment with preoperative immunoradiation followed by surgery. Calculated through log-rank test and Cox proportional hazards (PH) model.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 100 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Written informed consent and any locally-required authorization obtained.
  • Histologically-confirmed diagnosis of stage III non-small cell lung cancer (NSCLC)
  • Age≥18 years
  • Life expectancy >6 months
  • Body weight >30kg
  • Subjects with non-small cell lung cancer deemed surgically resectable by an attending thoracic surgeon with lobectomy
  • ECOG Performance Status 0-1
  • Normal bone marrow and organ function on routine laboratory tests, as defined in section 4.1
  • Evidence of post-menopausal status or negative urinary/serum pregnancy test for female pre-menopausal subjects. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause.
  • Ability to understand and willingness of sign consent form
  • Willingness to comply with the protocol for the duration of the study

Exclusion Criteria:

  • Involvement in the planning and/or conduct of the study (includes AstraZeneca staff and staff at the study site)
  • Prior investigational therapy within 28 days/at least 5 half-lives before study drug administration
  • Prior chest radiation
  • Prior history of interstitial lung disease or pneumonitis requiring corticosteroids, or active non-infectious pneumonitis
  • Patients only suitable for surgical management with pneumonectomy, deemed by an attending thoracic surgeon
  • Prior therapy with PD-1, PD-L1, CTLA-4 or anti-cancer vaccines, including durvalumab and tremelimumab
  • Participation in another clinical study with an investigational product in the last 4 weeks or equivalent of 5 half-lives of the first dose of study treatment, whichever is shorter
  • History of another primary malignancy except for: malignancy treated with curative intent and with no known active disease for the last 5 years, adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease, adequately treated carcinoma in situ without evidence of disease e.g., cervical cancer in situ
  • Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab or tremelimumab. The following are exceptions to this criterion:

    • Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra articular injection)
    • Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent
    • Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication)
  • Any unresolved toxicity (>CTCAE grade 2) from previous anti-cancer therapy
  • Subjects with irreversible toxicity that is not reasonably expected to be exacerbated by the investigational product may be included (e.g., hearing loss, peripherally neuropathy)
  • Any concurrent chemotherapy, IP, biologic, or hormonal therapy for cancer treatment. Concurrent use of hormonal therapy for non-cancer-related conditions (e.g., hormone replacement therapy) is acceptable
  • Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks of the first dose of study drug.
  • Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of IP. Note: Local surgery of isolated lesions for palliative intent is acceptable
  • History of allogenic organ transplantation.
  • Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc]). The following are exceptions to this criterion (vitiligo or alopecia; hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement; any chronic skin condition that does not require systemic therapy; active disease in the last 5 years may be included but only after consultation with the study physician; celiac disease controlled by diet alone.)
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, active bleeding diatheses including any subject known to have evidence of acute or chronic hepatitis B, hepatitis C or human immunodeficiency virus (HIV), or psychiatric illness/social situations that would limit compliance with study requirements or compromise the ability of the subject to give written informed consent
  • Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice), hepatitis B (known positive HBV surface antigen (HBsAg) result), hepatitis C, or human immunodeficiency virus (positive HIV 1/2 antibodies). Subjects with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Subjects positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.
  • Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab or tremelimumab
  • Female subjects who are pregnant, breast-feeding or male or female patients of reproductive potential who are not employing an effective method of birth control.
  • Any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study result.
  • Known allergy or hypersensitivity to IP or any excipient
  • Uncontrolled psychiatric illness/social situations that would limit compliance with study requirements or compromise the ability of the subject to give written consent
  • Any condition that, in the opinion of the investigator would interfere with evaluation of study treatment or interpretation of patient safety or study results.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03237377


Contacts
Layout table for location contacts
Contact: Jarushka Naidoo, MD 410-550-2646 jnaidoo1@jhmi.edu
Contact: Stella Krawiec 410-502-1962 skrawie1@jhmi.edu

Locations
Layout table for location information
United States, Maryland
Johns Hopkins Bayview Medical Center Recruiting
Baltimore, Maryland, United States, 21224
Contact: Jarushka Naidoo, MD    410-550-2646    jnaidoo1@jhmi.edu   
Contact: Stella Krawiec, M.A.    410-502-1962    skrawie1@jhmi.edu   
Sponsors and Collaborators
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
AstraZeneca
Investigators
Layout table for investigator information
Principal Investigator: Jarushka Naidoo, MD Johns Hopkins University

Layout table for additonal information
Responsible Party: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
ClinicalTrials.gov Identifier: NCT03237377    
Other Study ID Numbers: J1772
IRB00127418 ( Other Identifier: JHM IRB )
ESR-16-12244 ( Other Identifier: AstraZeneca )
First Posted: August 2, 2017    Key Record Dates
Last Update Posted: September 23, 2019
Last Verified: September 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Durvalumab
Tremelimumab
Antineoplastic Agents, Immunological
Antineoplastic Agents